🇺🇸 FDA
Patent

US 11339393

Compositions for modulating C9ORF72 expression

granted A61PA61P25/00A61P25/16

Quick answer

US patent 11339393 (Compositions for modulating C9ORF72 expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P25/00, A61P25/16, A61P25/28